Advertisement
As part of the 2007 acquisition agreement between Mylan Inc. (Dey's parent company) and Merck KGaA (Dey's former parent company), Merck KGaA is responsible for paying the full amount of this settlement as well as all costs and other expenses associated with pending and future-related Medicaid reimbursement lawsuits involving Dey.
Advertisement
As part of the settlement, the state acknowledges that the settlement does not constitute admission or evidence of fault, liability or unlawful conduct by Dey.
Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey L.P. puts patients first through its development of innovative and affordable therapies. The Web sites for Dey L.P. include www.dey.com, www.accuneb.com, www.curosurfusa.com, www.cyanokit.com, www.duoneb.com, www.epipen.com and www.perforomist.com.
SOURCE Dey, L.P.
